ZVRA

Zevra Therapeutics Stock Analysis

AI Rating

Good
  • Quality4/10
  • Growth↑ 8/10
  • Momentum↓ 4/10
Zevra Therapeutics sales and earnings growth
ZVRA Growth
Good
  • Revenue Y/Y↑ 244.60%
  • EPS Y/Y↑ 122.75%
  • FCF Y/Y↑ 66.05%
Zevra Therapeutics gross and profit margin trends
ZVRA Profitability
Great
  • Gross margin ↑ 80.70%
  • EPS margin↑ 41.90%
  • ROIC↑ 37.20%
Zevra Therapeutics net debt vs free cash flow
ZVRA Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 0.4
  • Interest coverage↑ 7.5

Zevra Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗